Latest Information
Below you can access the latest press releases, financial reports, corporate governance documents and more. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.
-
LMNL Corporate Presentation November
-
Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center
Prometic Plasma Resources (USA) Inc., has received U.S. Food and Drug Administration (“FDA”) approval for its plasma collection center located in Amherst, NY.
-
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
LMNL today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.
-
Liminal BioSciences Presents Two Case Histories on Investigational Intravenous Plasminogen (Human) Replacement Therapy at The ASH Conference
LMNL announced the presentation of two scientific posters highlighting potential activity of intravenous Ryplazim® (plasminogen) on infertility and acute airway obstruction in patients with C-PLGD.
-
Press Releases
Read More -
Quarterly Report Q3 2020
-
Quarterly Report Q2 2020
-
Quarterly Report Q1 2020
-
Financial Reports
Read Now -
Board Committees - Chairs' Mandate 2020
-
Mandate of the Chair of the Board 2020
-
LMNL Share Price
View Now -
CEO Position Description 2020
-
Corporate Governance
Read More -
Loading More...